The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Objective
Migraine, a prevalent and debilitating disease, involves complex pathophysiology possibly including inflammation and heightened pain sensitivity. The current study utilized the complete Freund's adjuvant (CFA) model of inflammation, with onabotulinumtoxinA (BoNT/A) as a treatment of interest due to its use in clinical migraine management. Using an animal model, the study sought to investigate the role of BoNT/A in modulating CFA-induced inflammation, alterations in pain sensitivity, and the regulation of calcitonin gene–related peptide (CGRP) release. Further, we aimed to assess the changes in SNAP-25 through western blot analysis to gain insights into the mechanistic action of BoNT/A.

Methods
BoNT/A or control was administered subcutaneously at the periorbital region of rats 3 days before the induction of inflammation using CFA. Periorbital mechanical sensitivity was assessed post-inflammation, and alterations in CGRP release were evaluated. Changes in SNAP-25 levels were determined using western blot analysis.

Results
Upon CFA-induced inflammation, there was a marked increase in periorbital mechanical sensitivity, with the inflammation side showing increased sensitivity compared to other periorbital areas. BoNT/A did decrease the withdrawal thresholds in the electronic von Frey test. Despite not being able to observe differences in pain thresholds or CGRP release, BoNT/A reduced baseline release under CFA inflamed conditions. Analysis of SNAP-25 levels in the trigeminal ganglion revealed both intact and cleaved forms that were notably elevated in BoNT/A-treated animals. These findings, derived from western blot analysis, suggest an effect on neurotransmitter release.

Conclusion
Our investigation highlights the role of BoNT/A in reducing baseline CGRP in the context of inflammation and its involvement in SNAP-25 cleavage. In contrast, BoNT/A did not appear to alter facial pain sensitivity induced by inflammation, suggesting that mechanisms other than baseline CGRP could be implicated in the elevated thresholds in the CFA model.
OriginalsprogEngelsk
TidsskriftHeadache
ISSN0017-8748
DOI
StatusE-pub ahead of print - 2024

Bibliografisk note

Funding Information:
and declare no conflicts of interest pertaining to the submitted work. received a research grant from Allergan to perform the present study. Philip Victor Reducha, Jesper Peter B\u00F6mers, Kristian Agmund Haanes Lars Edvinsson

Funding Information:
Kristian Agmund Haanes was supported by a Lundbeck Foundation Fellowship (R345\u20102020\u20101977). Lars Edvinsson received a research grant from Allergan to investigate the effect of BoNT/A in the inflammation model. The funders did not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

Publisher Copyright:
© 2024 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.

ID: 391677575